Conventional magnetic resonance imaging has good sensitivity for detecting very early breast cancers, and may be a valuable for screening women who are at high risk for breast cancer. However, its specificity is inadequate, particularly given its high sensitivity. As a result there is a concern that MRI scans lead to unnecessary treatment. We propose to significantly increase sensitivity and specificity with improved spectral, temporal and spatial sampling (MRITSS). MRITSS has two components. High spectral and spatial resolution MRI provides a high resolution water spectrum associated with each image voxel, and the water spectral lineshape is analyzed to produce improved anatomic and functional MR images. High temporal and spatial resolution imaging during contrast media uptake and washout allows accurate measurement of perfusion and other physiologic parameters. We will test the hypothesis that the combination of these two approaches - MRITSS - improves specificity and sensitivity in the high risk population that would benefit most from MRI. We will study 'incidental'lesions that are found during clinical MRI screening, since these lesions are most susceptible to incorrect diagnosis. An additional research scan before biopsy will acquire data from an 'incidental lesion', using MRITSS. Conventional and MRITSS data will be evaluated using standard morphologic and functional parameters to arrive at a diagnosis. We will determine whether MRITSS increases specificity and sensitivity, using the pathologist's diagnosis as the gold standard. In addition, we will determine whether MRI parameters are correlated with genetic and biologic markers for cancer risk, including microvessel density, cell proliferation markers, VEGF receptors, and P53, HER2, BRCA1 and BRCA2. The study will include African American women who are at particularly high risk for aggressive early breast cancer. We will compare the MRI parameters for breast lesions in these women with those for the other women in the study. The research will have a significant impact on clinical managements of breast cancer. If the results demonstrate that MRITSS has high specificity for early breast cancer- this will support increased clinical use of MRI for screening high risk women, and integration of improved spectral, spatial, and temporal sampling into clinical MRI. In addition, the research provides an unusual opportunity to correlate MRI parameters with biological markers for malignancy in early breast cancers. This could lead to improved design of MRI protocols and interpretation of MR images. The research is an interdisciplinary collaboration between Radiologists, Oncologists, Surgeons, Pathologists, Medical Physicists, and Statisticians with strong track records in breast imaging and breast cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA125183-05
Application #
8137159
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
5
Fiscal Year
2010
Total Cost
$317,251
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Guindalini, Rodrigo Santa; Zheng, Yonglan; Abe, Hiroyuki et al. (2018) Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers. Clin Cancer Res :
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Zheng, Yonglan; Walsh, Tom; Gulsuner, Suleyman et al. (2018) Inherited Breast Cancer in Nigerian Women. J Clin Oncol 36:2820-2825
Wang, Shengfeng; Ogundiran, Temidayo; Ademola, Adeyinka et al. (2018) Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiol Biomarkers Prev 27:636-643
Debiasi, Márcio; Polanczyk, Carisi A; Ziegelmann, Patrícia et al. (2018) Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Front Oncol 8:156
Geeleher, Paul; Huang, R Stephanie (2017) Exploring the Link between the Germline and Somatic Genome in Cancer. Cancer Discov 7:354-355
Hon, Jason; Hwang, Michelle S; Charnetzki, Meara A et al. (2017) Kinetic characterization of the inhibition of protein tyrosine phosphatase-1B by Vanadyl (VO2+) chelates. J Biol Inorg Chem 22:1267-1279
Milne, Roger L (see original citation for additional authors) (2017) Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 49:1767-1778
Johnston, Henry Richard; Hu, Yi-Juan; Gao, Jingjing et al. (2017) Identifying tagging SNPs for African specific genetic variation from the African Diaspora Genome. Sci Rep 7:46398
Nath, Aritro; Wang, Jacqueline; Stephanie Huang, R (2017) Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia. Mol Diagn Ther 21:621-631

Showing the most recent 10 out of 203 publications